Bio-Tracking Security Inc. released some technical data today on the oil and gas reserves being acquired through Nord Oil. According to reports obtained by RSM Top Audit from the Russian Ministry of Geology, the acquisition consists primarily of two licenses to extract oil and gas from the Yemelyanov deposit located in the Sergiev District of Samara Region and a license for the Khlebnov area as well as substantial storage facilities.
Yemelyanov License
Located in the Sergiev District of Samara Region, 110 Km North-East of Samara. The Yemelyanov is an area allotment of 11.9 square kilometers. According to the reports from the Russian Ministry of Geology and license CMP No. 00676 Type H3, the Yemelyanov has 2,130,000 cubic meters and 2,580,000 m3 respectively of oil in place at 876 and 908 density with less than 4.5 sulfur.
Khelbnov License
Located in the Tatisshchev District of Saratov region, 24 Km North West of Saratov. The total area allotment is 8.3 square kilometers. According to the report from the Russian Ministry of Geology and license SRT No. 11560 Type NP, the Khlebnov field adds a further 1,200,000 m3 of lighter (805) oil in place with residual sulfur.
''Under our preliminary plan of action, we expect that with conventional recovery technology that our properties will produce an excess of 6.5 million barrels over the next several years,'' said Dr. Matossian, President of Great West Oil and Gas, and industry consultant to the board of directors. ''We believe that according to today's oil prices that over US$350 million of oil will be extracted in the foreseeable near future and with additional properties, which can be acquired, Nord Oil can become a serious international producer,'' further added Dr. Matossian.
The company stated that they have plans to make their corporate website available with all technical and independent reports by the middle of August to provide investors and industry partners with the ability to evaluate the properties and their value.
Posts: 1052 | From: Coventry, RI, USA | Registered: Dec 2004
| IP: Logged |
posted
We still need them to release there PR's on Newswire instead of primezone....where do you guys get your news from?? I get mine usually from yahoo, and yahoo is not showing this pr anymore???? Kinda weird I don't see it in msn money either!
Posts: 1052 | From: Coventry, RI, USA | Registered: Dec 2004
| IP: Logged |
quote:Originally posted by rishid: Seems like this is a good LT hold? I am going to get in tomorrow, still worth it?
Ur kidding right? This is a great LT hold!!!
I don't see this stock being under .05 for much longer, by next week we see what the future has in store for BTSI and NORD OIL
Posts: 1052 | From: Coventry, RI, USA | Registered: Dec 2004
| IP: Logged |
posted
Thanks TotalZen....but what i am getting at is nobody is going to see this PR unless they go looking for it...I don't see it on any stock news sites!
Posts: 1052 | From: Coventry, RI, USA | Registered: Dec 2004
| IP: Logged |
quote:Originally posted by TotalZen: I hear ya, and it's only occurring for this stock, way weeeeird.
I smell a conspiracy.
LOL...it's gotta be them commie's...lol
I will rent a plane and pull the PR behind me through NY City and Boston!!!
Posts: 1052 | From: Coventry, RI, USA | Registered: Dec 2004
| IP: Logged |
posted
Bond Could you point me in the direction of the information used to make statement #1. Please!
Thanks Rick
quote:Originally posted by bond006: NORD Oil INT'L, HUGE Positives here! Per 8k
1.) We are Graduating (from the pinksheets) on the closing date to the OTCBB exchange!...With sponsored MM representation.
2.) NORD Oil is Debt Free!!!!
3.) The 'real' NORD management steps in after closing date!
4.) 180 million of the Post-Split 216 million O/S will be RESTRICTED! Wich Leaves ONLY 36 Million in the public float!
5.) Finantial Statements are on there way to us...Also prior to Closing!
WHEREAS, Bio-Tracking desires to acquire all of the NORD Shares in exchange for 180,000,000 restricted shares of the Common Stock of Bio-Tracking the (“Bio-Tracking Shares”) (the “Share Exchange”).
Section 7.03. Appointment of NORD’s Board Nominees; Resignation of Current Directors. At the Closing, Bio-Tracking shall deliver or cause to be delivered the resignations and releases and indemnification of all the officers of Bio-Tracking. Bio-Tracking shall also cause, at closing that all the directors of Bio-Tracking shall deliver seriatim their resignations together with releases and indemnifications in favor of two NORD nominees and that NORD shall as a result have 2 two out of 5 five directors post closing.
(a) “Closing” shall mean the release of the Bio-Tracking Shares to the Shareholders and the NORD Shares to Bio-Tracking upon completion of the terms and conditions of this Agreement, which shall be held at the offices of Finkelstein Capital Inc. at 1 Place Ville Marie, Suite 2821, Montreal, Quebec, H3B 4R5 on June 15, 2005 (the “Closing Date”);
posted
I'm reading through 8-k filed...out of the 36 mil outstanding shares also 6 mil shares finders fee goes to Finkelstein Capital and then 1.2 mil after completion for success fee. So that only leaves 28.8mil
-------------------- If your reading this then obviously you have time to do research before you buy or sell a stock Posts: 143 | Registered: Jun 2005
| IP: Logged |
"Section 7.05. Quotation on OTC/BB. Prior to the Closing Date, Bio-Tracking shall on a best effort basis have completed its application ready to be filed, through a licensed market maker, for approval of its common stock to be quoted on the OTC/Bulletin Board."
posted
Section 7.04. Filing of Periodic Reports. From the date of this Agreement up to the Closing Date, Bio-Tracking will file with the U.S. Securities and Exchange Commission any and all periodic reports required to be filed by Bio-Tracking pursuant to Section 13(g) of the Securities Exchange Act of 1934 and at the Closing, Bio-Tracking shall be current in such filings for the past two (2) years. All such reports filed from the date of this Agreement shall be, as of the time of filing, accurate, not misleading and complete in all material respects and the financial statements included therewith shall have been prepared in accordance with generally accepted accounting principles.
Section 7.05. Quotation on OTC/BB. Prior to the Closing Date, Bio-Tracking shall on a best effort basis have completed its application ready to be filed, through a licensed market maker, for approval of its common stock to be quoted on the OTC/Bulletin Board.
-------------------- If your reading this then obviously you have time to do research before you buy or sell a stock Posts: 143 | Registered: Jun 2005
| IP: Logged |
posted
Section 8.01. Recapitalization . The Shareholders shall not vote in favour of any reverse split of Bio-Tracking’s stock that is proposed by the Board of Directors of Bio-Tracking or any shareholders of Bio-Tracking at any time during the two (2) year period that commences on the Closing Date except for the planned 1:12 reverse split.
-------------------- If your reading this then obviously you have time to do research before you buy or sell a stock Posts: 143 | Registered: Jun 2005
| IP: Logged |
posted
Section 4.05. Capitalization. Schedule 4.05 sets forth the authorized capitalization of Bio-Tracking which is the only class of the Company’s capital stock outstanding, as of the date of this Agreement. There are no outstanding options or warrants of Bio-Tracking, save for those disclosed in Schedule 4.05. All of the outstanding shares of Bio-Tracking's common stock, numbering no more and no less than 340,000,000 shares as at closing, are duly authorized, validly issued, fully paid and non-assessable and free of pre-emptive rights and all such shares issued during the last 24 months were issued in compliance with all applicable U.S. securities laws and Bio-Tracking will file with appropriate authorities to perform a 1:12 reverse split, whereby the total issued and outstanding of the common shares of Bio-Tracking will be approximately 28,333,000 but no more than 30,000,000 and the shares for the acquisition of NORD will be issued post reverse and therefore Bio-Tracking will have a total of 216,000,000 common shares outstanding.
-------------------- Nothing moves a sub like news!!! Posts: 3346 | From: Leominster,MA,US | Registered: Jul 2003
| IP: Logged |
"Section 7.05. Quotation on OTC/BB. Prior to the Closing Date, Bio-Tracking shall on a best effort basis have completed its application ready to be filed, through a licensed market maker, for approval of its common stock to be quoted on the OTC/Bulletin Board."
posted
Section 7.02. No Change in Capitalization. On the Closing Date, the capitalization of Bio-Tracking shall be as represented in Section 4.05, plus the issuances as contemplated in Section 5.10 hereof.
Section 7.03. Appointment of NORD’s Board Nominees; Resignation of Current Directors. At the Closing, Bio-Tracking shall deliver or cause to be delivered the resignations and releases and indemnification of all the officers of Bio-Tracking. Bio-Tracking shall also cause, at closing that all the directors of Bio-Tracking shall deliver seriatim their resignations together with releases and indemnifications in favor of two NORD nominees and that NORD shall as a result have 2 two out of 5 five directors post closing.
Section 7.04. Filing of Periodic Reports. From the date of this Agreement up to the Closing Date, Bio-Tracking will file with the U.S. Securities and Exchange Commission any and all periodic reports required to be filed by Bio-Tracking pursuant to Section 13(g) of the Securities Exchange Act of 1934 and at the Closing, Bio-Tracking shall be current in such filings for the past two (2) years. All such reports filed from the date of this Agreement shall be, as of the time of filing, accurate, not misleading and complete in all material respects and the financial statements included therewith shall have been prepared in accordance with generally accepted accounting principles.
Section 7.05. Quotation on OTC/BB. Prior to the Closing Date, Bio-Tracking shall on a best effort basis have completed its application ready to be filed, through a licensed market maker, for approval of its common stock to be quoted on the OTC/Bulletin Board.
Section 7.06. Financial Liabilities at Closing. As of the Closing Date, Bio-Tracking shall have no assets and no liabilities.
Section 7.07. Board and Shareholder Approval. (a) Prior to the Closing, Bio-Tracking shall obtain the approval of its Board of Directors of this Agreement and the transactions contemplated hereby.
(b) Bio-Tracking shall cause an Information Statement on Schedule 14C to be filed with the SEC and mailed to its shareholders of record disclosing that Bio-Tracking has entered into this Agreement and also the transactions contemplated hereby. Such Information Statement shall also provide that Bio-Tracking intends to change its name to “Nord Oil International Inc.”, along with any other action of which Bio-Tracking requires shareholder approval in order to close this Agreement in accordance with the terms hereof. Shareholders of Bio-Tracking holding at least a majority of Bio-Tracking’s issued and outstanding shares of common stock, as of the record date, shall approve of this Agreement and the transactions contemplated hereby either by proxy or written consent.
Section 7.08. Cancellation Fee. In the event that the transactions contemplated by this Agreement are not closed by June 15, 2005 as the result of a material misrepresentation by Bio-Tracking in any of its periodic reports filed with the SEC through to current filing or any breach by Bio-Tracking of its obligations hereunder or a material misrepresentation by Bio-Tracking to NORD, Bio-Tracking shall pay to NORD a cancellation fee of US$5,000.
ric section 7.05 excuse me i was out thats the way i read it
Posts: 6008 | From: phoenix az | Registered: Mar 2005
| IP: Logged |
posted
well everybody i think the word is going to be out one way or the other the more dd i do the better this looks it looks so far to be the real deal i just picked up another 100k to day forgot i had the dam order in at .025 got home and it filled gltq
ric i am sorry i was out but it looked like the guys got the answer for me i will post the whole thing but it is very boring
Posts: 6008 | From: phoenix az | Registered: Mar 2005
| IP: Logged |
On June 15, we completed our acquisition of Nord Oil, Inc., a Delaware corporation, pursuant to a Shares Exchange Agreement, the form of which is attached as Exhibit 2.1 hereto. At the effective time of the merger, the Shareholders of Nord Oil, Inc. agreed to exchange their Nord Oil, Inc. shares of common stock for the Bio-Tracking Security Systems, Inc. shares of common stock and Bio-Tracking Security Systems, Inc. agreed to exchange Bio-Tracking Security Systems, Inc. shares of common stock for the Nord Oil, Inc. shares of common stock. Consequently, Nord Oil, Inc. shall become a wholly owned subsidiary of Bio-Tracking Security Systems, Inc.
All of the outstanding shares of Nord Oil, Inc. common stock shall be exchanged by virtue of the merger into shares of our common stock (the “Merger Securities”). Each Shareholder of Nord Oil, Inc. shall surrender their outstanding shares of Nord Oil, Inc. common stock existing. Until so surrendered, any outstanding certificates or other documentation representing outstanding shares of Nord Oil, Inc. common stock, shall be deemed for all corporate purposes to be surrendered.
The foregoing description of the Agreement and Plan of Merger is qualified in its entirety by reference to the Agreement and Plan of Merger, the form of which is attached as Exhibit 2.1 hereto and incorporated herein by reference.
This report contains forward-looking statements as the term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "potential" or "continue" or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors. Therefore, actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. For a list and descriptions of such risks and uncertainties, see the reports filed by us with the Securities and Exchange Commission.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(a) Financial statements of business acquired.
The financial statements required by this Item 9(a) will be filed by amendment to the Form 8-K filed with the Securities and Exchange Commission on March 28, 2005, within the period permitted by Item 9(a)(4) of Form 8-K.
(b) Pro Forma financial information
The pro forma financial information required by this Item 9(b) will be filed by amendment to the Form 8-K filed with the Securities and Exchange Commission on March 28, 2005, within the period permitted by Item 9(a)(4) of Form 8-K.
(c) Exhibits
Exhibits Description 2.1 Share Exchange Agreement by and between Nord Oil, Inc. and Bio-Tracking Security Systems, Inc., dated June 2, 2005.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIO-TRACKING SECURITY SYSTEMS INC.
DATE: June 28, 2005 By: /s/ Jean-Francois Amyot
-------------------------------------------------------------------------------- Jean-Francois Amyot Chairman of the Board of Directors
THIS SHARE EXCHANGE AGREEMENT (this “Agreement”), effective as of June 2 2005, (the "Effective Date"), is entered into by and between the shareholders of the Nord Oil (“NORD”), as listed on Exhibit A hereto (the “Shareholders”) and Bio-Tracking Security Inc., a Florida corporation (“BIO-TRACKING”).
WHEREAS, the Shareholders are the registered and beneficial owners of all of the issued and outstanding shares of Common Stock, $0.001 par value, of NORD (the “NORD Shares”);
WHEREAS, Bio-Tracking is a publicly reporting company registered with the U.S. Securities and Exchange Commission, whose stock currently trades under the symbol BTSI;
WHEREAS, Bio-Tracking desires to acquire all of the NORD Shares in exchange for 180,000,000 restricted shares of the Common Stock of Bio-Tracking the (“Bio-Tracking Shares”) (the “Share Exchange”).
WHEREAS, the parties to this Agreement have agreed to the Share Exchange subject to the terms and conditions set forth below.
NOW THEREFORE THIS AGREEMENT WITNESSES that for and in consideration of the mutual premises and the mutual covenants and agreements contained herein, the parties covenant and agree each with the other as follows:
ARTICLE I DEFINITIONS
Section 1.01. The following terms shall have the following respective meanings:
(a) “Closing” shall mean the release of the Bio-Tracking Shares to the Shareholders and the NORD Shares to Bio-Tracking upon completion of the terms and conditions of this Agreement, which shall be held at the offices of Finkelstein Capital Inc. at 1 Place Ville Marie, Suite 2821, Montreal, Quebec, H3B 4R5 on June 15, 2005 (the “Closing Date”);
(b) “NORD” shall have the meaning ascribed thereto in the first paragraph of this Agreement;
(c) “NORD Shares” shall have the meaning ascribed thereto in the second paragraph of this Agreement;
(d) “Effective Date” shall have the meaning ascribed thereto in the first paragraph of this Agreement;
(e) “Escrow Agent” shall have the meaning ascribed thereto in Section 2.02(c) hereof;
(f) “Escrow Agreement” shall mean that certain Escrow Agreement to be entered into simultaneously with this Agreement by and among NORD, Bio-Tracking and Joseph Emas Attorney;
(g) the “Financial Statements” shall have the meaning ascribed thereto in Section 3.10 hereto;
(h) “Share Exchange” shall have the meaning ascribed thereto in the fourth paragraph of this Agreement;
(i) “Shareholders” shall have the meaning ascribed thereto in the first paragraph of this Agreement;
(j) “Bio-Tracking” shall have the meaning ascribed thereto in the first paragraph of this Agreement; and
(k) “Bio-Tracking Shares” shall have the meaning ascribed thereto in the fourth paragraph of this Agreement.
ARTICLE II EXCHANGE OF STOCK
Section 2.01. Exchange. Upon the terms and subject to the conditions of this Agreement, the Shareholders agree to exchange the NORD Shares for the Bio-Tracking Shares and Bio-Tracking agrees to exchange the Bio-Tracking Shares for the NORD Shares at the Closing or as soon as it is legal possible, whereas the shares will be deemed to be issued at the time of closing. The parties intend that the Share Exchange shall qualify as a tax-free reorganization under Section 368 of the Internal Revenue Code. However, Bio-Tracking makes no representations or warranties regarding the qualification of the Share Exchange as “tax free”. Bio-Tracking shall cooperate with NORD in executing any reasonably necessary documents to qualify the Share Exchange as tax free. So far as such agreements do not or could not cause Bio-Tracking or its shareholders to incur any liability or further obligation.
Section 2.02. Delivery of Stock; Escrow.
(a) Upon the execution hereof, the Shareholders shall deliver to the Escrow Agent all of the stock certificates representing the NORD Shares, duly endorsed in blank and accompanied by a medallion signature guarantee;
(b) Upon execution hereof, Bio-Tracking shall deliver to the Escrow Agent an issuance letter representing the stock certificates to be issued of Bio-Tracking Shares in the names and denominations as set forth on Exhibit B hereto, with the express understanding and agreement of all parties hereto that in the event that the Closing does not occur and the Bio-Tracking Shares are returned to Bio-Tracking by the Escrow Agent pursuant to the Escrow Agreement, then Bio-Tracking may present the Bio-Tracking Shares to its transfer agent for cancellation without any signed stock powers from any of the Shareholders. If the Closing does not occur the NORD Shares shall be returned to the Shareholders.
(c) The execution and delivery of this Agreement shall take place at the offices of Finkelstein Capital Inc. at 1 Place Ville Marie, Suite 2821, Montreal, Quebec, H3B 4R4 on June 15, 2005; or by counterpart signatures to be sent to such offices by facsimile transmission to 514-448-6712. All documents and instruments required to be delivered at the Closing shall be delivered into escrow to be held by Joseph Emas. (the “Escrow Agent”), pursuant to the Escrow Agreement, pending completion of the covenants and conditions to Closing as set forth in Articles V, VI and VII hereto.
ARTICLE III REPRESENTATIONS AND WARRANTIES OF SHAREHOLDERS
Section 3.01. Organization, Standing and Authority; Foreign Qualification. (a) NORD is a corporation duly organized, validly existing and in good standing under the laws of Delaware with all requisite power and authority to enter into, and perform the obligations under this Agreement. NORD has all requisite power and authority to own, lease and operate its assets, properties and business and to carry on its business as now being and as heretofore conducted.
(b) The Company is duly qualified or otherwise authorized as a foreign corporation to transact business and is in good standing in each jurisdiction set forth in Schedule 3.01 which are the only jurisdictions in which such qualification or authorization is required by law. No other jurisdiction has claimed, in writing or otherwise, that NORD is required to qualify or otherwise be licensed therein. Except as set forth in Schedule 3.01, NORD does not file any franchise, income or other tax returns in any other jurisdiction based upon the ownership or use of property therein or the derivation of income therefrom.
Section 3.02. Capitalization. Schedule 3.02 sets forth the authorized capitalization of NORD and the ownership of each outstanding share of Common Stock, which is the only class of the Company’s capital stock that is outstanding. All of the outstanding shares of Common Stock of NORD are duly authorized, validly issued, fully paid and non-assessable and free of preemptive rights.
Section 3.03. Certificate of Incorporation and By-Laws. The Shareholders have heretofore delivered to Bio-Tracking true, correct and complete copies of the Certificate or Articles of Incorporation (certified by the appropriate official for Canadian Corporations) and By-laws or comparable instruments (certified by the corporate secretary thereof) of NORD. The minute books of NORD accurately reflect all actions taken at all meetings and consents in lieu of meetings of its stockholders, and all actions taken at all meetings and consents in lieu of meetings of each of their boards of directors and all committees. For instance the cut off date for circulation and acceptance of minutes of Board of Director Meetings is 90 days from close of Board of Directors Meetings with the minutes deemed as accepted by the majority vote.
Section 3.04. Execution and Delivery. This Agreement has been duly executed and delivered by each Shareholder and each constitutes the valid and binding agreement of each Shareholder enforceable against the Shareholders in accordance with its terms.
Section 3.05. Consents and Approvals. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby and thereby in accordance with the terms and conditions hereof and thereof do not require any Shareholder or NORD to obtain any consent, approval or action of, or make any filing with or give any notice to, any person or entity.
Section 3.06. No Conflict. The execution, delivery and performance of each of this Agreement and the consummation of the transactions contemplated hereby and thereby in accordance with the terms and conditions hereof and thereof will not (a) violate any provisions of the Articles or Certificate of Incorporation, By-laws or other charter or organizational document of NORD; (b) violate, conflict with or result in any modification of the effect of, otherwise give any other contracting party the right to terminate, or constitute (or with notice or lapse of time or both, constitute) a default under, and Contract to which any Shareholder or NORD is a party to by or to which any of them or any of their respective assets or properties may be bound or subject; (c) violate any order, judgment, injunction, award or decree of any court, arbitrator or governmental or regulatory body against, or binding upon or any agreement with, or condition imposed by, any governmental or regulatory body, foreign or domestic, binding upon any Shareholder or NORD or upon the NORD Shares or the properties or business of NORD; (d) violate any statute, law or regulation of any jurisdiction as such statute, law or regulation relates to any Shareholder or NORD; or (e) result in the breach of any of the terms or conditions of, constitute a default under, or otherwise cause an impairment of, any Permit.
Section 3.07. Title to Stock. Each Shareholder has valid title to their respective portion of the NORD Shares free and clear of all liens or encumbrances, including, without limitation, any community property claim. Upon delivery of the NORD Shares to be made on the Closing Date as herein provided, Bio-Tracking shall acquire good and marketable title thereto, free and clear of any Lien, including, without limitation, any community property claim.
Section 3.08. Options or Other Rights. (a) There is no outstanding right, subscription, warrant, call NORD preemptive right, option, contract or other agreement of any kind to purchase or otherwise to receive from any Shareholder or from NORD any of the outstanding, unauthorized or treasury shares of the Common Stock of NORD; except as otherwise specified in schedule “A” attached; and (b) there is no outstanding security of any kind convertible into any security of NORD, and, except as aforesaid, there is no outstanding contract or other agreement to purchase, redeem or otherwise acquire any of the NORD Shares.
Section 3.09. Material Information. This Agreement, the Schedules hereto, the Financial Statements of NORD and all other information provided in writing by the Shareholders or NORD or representatives thereof to Bio-Tracking, taken as a whole, do not contain any untrue statement of a material fact or omit to state a material fact necessary to make any statement contained herein or therein not misleading. There are no facts or conditions, which have not been disclosed to Bio-Tracking in writing which, individually or in the aggregate, could have a material adverse effect on NORD or a material adverse effect on the ability of any Shareholder to perform any of his or her obligations pursuant to this Agreement.
Section 3.10. Financial Statements. The Shareholders have or will have prior to the Closing furnished to Bio-Tracking certain financial statements of NORD as set forth in Section 5.11 hereof (the “Financial Statements”). The Financial Statements shall be true, correct and complete in all material respects and fairly present the financial condition of NORD and the results of its operations for the period then ended and shall be prepared in conformity with U.S. generally accepted accounting principles applied on a consistent basis. Said statements will be as at December 31st year end going back 2 years following United States G.A.A.P. rules.
Section 3.11. Absence of Certain Changes. Since the date of the Financial Statements, there has been no event, change or development which could have a material adverse effect on NORD.
Section 3.12. Undisclosed Liabilities. Except as reflected or reserved against in the Financial Statements, as of and for the period reflected therein, NORD was not on that date subject to, and since that date NORD has not incurred, any direct or indirect indebtedness, liability, claim, loss, damage, deficiency, obligation or responsibility, fixed or unfixed, choate or inchoate, liquidated or unliquidated, secured or unsecured, accrued, absolute, contingent or otherwise, of a kind required by generally accepted accounting principles to be reflected or reserved against on a financial statement (“Liabilities”), which individually or in the aggregate exceeds $10,000.
Section 3.13. Operations of the Company. Except as contemplated by this Agreement, or as otherwise specified in schedule “B” and itemized with respect to section 3.13 paragraphs (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), and (k), since the date of the Financial Statements, NORD has not (a) amended its Certificate or Articles of Incorporation or By-laws or merged with or into or consolidated with any other person or entity, subdivided or in any way reclassified any shares of its capital stock or changed or agreed to change in any manner the rights of its outstanding capital stock or the character of its business; (b) issued, reserved for issuance, sold or redeemed, repurchased or otherwise acquired, or issued options or rights to subscribe to, or entered into any contract or commitment to issue, sell or redeem, repurchase or otherwise acquire, any shares of its capital stock or any bonds, notes, debentures or other evidence or indebtedness; (c) incurred any indebtedness for borrowed money or incurred or assumed any other Liability in excess of $10,000 in any one case (or, in the aggregate, in the case of any related series of occurrences) or $25,000 in the aggregate; (d) declared or paid any dividends or declared or made any other distributions of any kind to its stockholders; (e) made any change in its accounting methods or practices or made any change in depreciation or amortization policies, except as required by law or generally accepted accounting principles; (f) made any loan or advance to any of its stockholders or to any of its directors, officers or employees, consultants, agents or other representatives, or made any other loan or advance, otherwise than in the ordinary course of business; (g) entered into any lease (as lessor or lessee) under which NORD is obligated to make or would receive payments in any one year of $10,000 or more; sold, abandoned or made any other disposition of any of its assets or properties; granted or suffered any Lien on any of its assets or properties; entered into or amended any contracts to which it is a party, or by or to which it or its assets or properties are bound or subject which if existing on the date hereof would be required to be disclosed in Schedule 3.17; (h) made any acquisition of all or a substantial part of the assets, properties, securities or business of any other person or entity; (i) paid, directly or indirectly, any of its material Liabilities before the same became due in accordance with its terms or otherwise than in the ordinary course of business; (j) terminated or failed to renew, or received any written threat (that was no subsequently withdrawn) to terminate or fail to renew, any contract that is or was material to the assets, Liabilities, business, property, operations, prospects, results of operations or condition (financial or otherwise of NORD; or (k) entered into any other contract or other transaction that materially increases the Liabilities of NORD.
Section 3.14 Compliance with Laws. NORD is not in violation of any applicable order, judgment, injunction, award or decree nor is it in violation of any Federal, state, local or foreign law, ordinance or regulation or any other requirement of any governmental or regulatory body, court or arbitrator, other than those violations which, in the aggregate, would not have a material adverse effect on NORD, neither NORD or any Shareholder has received written notice that any violation is being alleged.
Section 3.15. Actions and Proceedings. There are no outstanding orders, judgments, injunctions, awards or decrees of any court, governmental or regulatory body or arbitration tribunal against or involving NORD, or against or involving any of the NORD Shares. There are no actions, suits or claims or legal, regulatory, administrative or arbitration proceedings pending or, to the knowledge of any of the Shareholders threatened against or involving NORD.
Section 3.16. Contracts. (a) Schedule 3.16 sets forth all of the (see schedule “C”) contracts hereinafter in this Section 3.16 referred to, to which NORD is a party or by or to which NORD or its assets or properties are bound or subject: (i) Contracts with any current or former officer, director, employee, consultant, agent or other representative having more than three months to run from the date hereof or providing for an obligation to pay and/or accrue NORD of $10,000 or more per annum, or providing for the payment of fees or other consideration in excess of $10,000 in the aggregate to any officer or director of NORD, or to any other entity in which NORD or Seller has an interest;
(ii) Contracts for the purchase or sale of equipment or services that contain an escalation, renegotiation or redetermination clause or that can be cancelled without liability, premium or penalty only on ninety days’ or more notice;
(iii) Contract for the sale of any of its assets or properties or for the grant to any Person of any preferential rights to purchase any of its or their assets or properties;
(iv) Contracts (including with limitation, leases of real property) calling for an aggregate purchase price or payments in any one year of more than $10,000 in any one case (or in the aggregate, in the case of any related series of Contracts);
(v) Contracts relating to the acquisition by NORD of any operating business of, or the disposition of any operating business by, any other Person;
(vi) executory Contracts relating to the disposition or acquisition of any investment or of any interest in any Person;
(vii) Contracts under which it agrees to indemnify any party, other than in the ordinary course of business or in amounts not in excess of $10,000, or to share tax liability of any party;
(viii) Contracts containing covenants of NORD not to compete in any line of business or with any person in any geographical area or covenants of any other person not to compete with NORD in any line of business or in any geographical area;
(ix) Contracts relating to the making of any loan by NORD;
(x) Contracts relating to the borrowing of money by NORD or the direct or indirect guaranty by NORD of any obligation for, or an agreement by NORD to service, the repayment of borrowed money, or any other contingent obligations in respect of indebtedness of any other Person, including, without limitation, (a) any Contract relating to the maintenance of NORD balances, (b) any Contract with respect to lines of credit, (c) any Contract to advance or supply funds to any other Person other than in the ordinary course of business, (d) any Contract to pay for property, products or services of any other Person even if such property, products or services are not conveyed, delivered or rendered, (e) any keep-well, make-whole or maintenance of working capital or earnings or similar Contract, or (f) any guaranty with respect to any lease or other similar periodic payments to be made by any other Person;
(xi) Contracts for or relating to computers, computer equipment, computer software or computer services; and
(xii) any other material Contract whether or not made in the ordinary course of business.
(b) There have been delivered or made available to Bio-Tracking true, correct and complete copies of each of the contracts set forth in Schedule 3.17 or in any other Schedule. Each such contract is valid, subsisting, in full force and effect and binding upon the parties thereto in accordance with its terms, and neither NORD nor any of NORD’s other affiliates, as the case may be, is in default in any respect under any of them.
Section 3.17. Liens. NORD has marketable title to all of its assets and properties free and clear of any lien.
Section 3.18. Officers, Directors and Key Employees. Except as specified in Schedule “D” attached, NORD does not have any contract or agreement with any of its officers, directors, employees or consultants whose annual salary equals or exceeds $25,000 or who received or has accrued in respect of such period a bonus equal to or in excess of $5,000; and NORD does not have any commitments or contracts to increase the wages or to modify the condition or terms of employment or consultancy of any of the employees or consultants of NORD, including the aggregate cost to NORD of all such commitments or contracts.
Section 3.19. Brokerage. As a result of the transaction 6,000,000 shares of Bio-Tracking will be issued by Bio-Tracking to pay a finders fee to Finkelstein Capital and or nominees as well as 1,200,000 “success” warrants to be issued to Finkelstein Capital and or nominee according to success factors as per the agreement between Finkelstein Capital and Bio-Tracking, whereby such agreement shall be entered into prior to the closing of the transaction and shall be subject to board approval.
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF BIO-TRACKING
Bio-Tracking represents and warrants to the Shareholders as follows:
Section 4.01. Organization, Standing and Authority of Bio-Tracking. Bio-Tracking is a corporation duly organized, validly existing and in good standing under the laws of the State of Nevada and has all requisite corporate power and authority to own or lease its assets as now owned or leased by it and to otherwise conduct its business. All corporate proceedings required by law or by the provisions of this Agreement to be taken by Bio-Tracking on or before the Closing Date in connection with the execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement have been or will be duly and validly taken.
Section 4.02. Execution and Delivery. This Agreement has been duly authorized, executed and delivered by Bio-Tracking and constitutes the valid and binding agreement of Bio-Tracking enforceable against Bio-Tracking in accordance with its terms.
Section 4.03. Consents and Approvals. The execution, delivery and performance by Bio-Tracking of this Agreement and the consummation by Bio-Tracking of the transactions contemplated hereby do not require Bio-Tracking to obtain any consent, approval or action of, or make any filing with or give any notice to, any person.
Section 4.04. No Conflict. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby in accordance with the terms and conditions hereof will not (a) violate any provision of the Articles or Certificate of Incorporation, By-laws or other charter or organizational document of Bio-Tracking; (b) violate, conflict with or result in the breach of any of the terms of, result in any modification of the effect of, otherwise give any other contracting party the right to terminate, or constitute (or with notice or lapse of time or both constitute) a default under, any contract to which Bio-Tracking is a party or by or to which its assets or properties may be bound or subject; (c) violate any order, judgment, injunction, award or decree of any court, arbitrator or governmental or regulatory body against, or binding upon, or any agreement with, or condition imposed by, any governmental or regulatory body, foreign or domestic, binding upon Bio-Tracking or upon the securities, assets or business of Bio-Tracking; or (d) violate any statute, law or regulation of any jurisdiction as such statute, law or regulation relates to Bio-Tracking or to the securities, properties or business of Bio-Tracking.
Section 4.05. Capitalization. Schedule 4.05 sets forth the authorized capitalization of Bio-Tracking which is the only class of the Company’s capital stock outstanding, as of the date of this Agreement. There are no outstanding options or warrants of Bio-Tracking, save for those disclosed in Schedule 4.05. All of the outstanding shares of Bio-Tracking's common stock, numbering no more and no less than 340,000,000 shares as at closing, are duly authorized, validly issued, fully paid and non-assessable and free of pre-emptive rights and all such shares issued during the last 24 months were issued in compliance with all applicable U.S. securities laws and Bio-Tracking will file with appropriate authorities to perform a 1:12 reverse split, whereby the total issued and outstanding of the common shares of Bio-Tracking will be approximately 28,333,000 but no more than 30,000,000 and the shares for the acquisition of NORD will be issued post reverse and therefore Bio-Tracking will have a total of 216,000,000 common shares outstanding.
Section 4.06. Brokerage. No broker or finder has acted, directly or indirectly, for Bio-Tracking, nor has Bio-Tracking incurred any obligation to pay any brokerage, finder’s fee or other commission in connection with the transactions contemplated by this Agreement, except for an obligation of Bio-Tracking to pay up to $25,000 to Finkelstein Capital for legal fees incurred in the preparation of this agreement.
Section 4.07. Certificate of Incorporation and By-Laws. Bio-Tracking has heretofore delivered to NORD true, correct and complete copies of the Certificate or Articles of Incorporation (certified by the Secretary of State) and By-laws or comparable instruments (certified by the corporate secretary thereof) of Bio-Tracking. The minute books of Bio-Tracking accurately reflect all actions taken at all meetings and consents in lieu of meetings of its stockholders, and all actions taken at all meetings and consents in lieu of meetings of its board of directors and all committees.
Section 4.08. Status of Bio-Tracking Shares. Upon consummation of the transactions contemplated by this Agreement, the Bio-Tracking Shares to be issued to the Shareholders, when issued and delivered, will be duly authorized, validly issued, fully paid and non-assessable and free of any and all liens, claims or encumbrances.
Section 4.09 No Bankruptcy. Neither Bio-Tracking nor its assets are the subject of any proceeding involving either a voluntary or an involuntary bankruptcy, insolvency or receivership.
Section 4.10 Absence of Certain Changes. Since December 1, 2004, there has not been any material adverse change in the financial condition, assets or liabilities of Bio-Tracking, and Bio-Tracking has not:
(a) Engaged in any material transaction outside the ordinary course of business;
(b) Made any capital expenditures other than in the ordinary course of business;
(c) Paid, loaned or advanced (other than the payment of salaries or reimbursement of expenses in the ordinary course of business) any amounts to, or sold, transferred or leased any properties or assets to or entered into any other transactions with any of its officers or directors, any of its affiliates, or any officer or director of its affiliates, as may be necessary to comply with Section 7.06 of this Agreement.
(d) Made any material change in any method of accounting or accounting practice;
(e) Incurred any material indebtedness or leasehold expense in excess of $5,000;
(f) Entered into any material guaranties or otherwise incurred or suffered to exist any material contingent liabilities;
(g) Paid or declared any dividend or other distribution in respect of its capital stock, or set aside any sums for the payment of any such dividend or other distribution;
(h) Agreed, whether in writing or otherwise, to do any of the foregoing; or
(i)Suffered any labor trouble or any controversies with any of its employees, or
(j) Entered into any contract, granting of option, future promise or contingent commitment with any director, shareholder, or any other third party for an aggregate amount in excess of $10,000.00.
Section 4.11 Contracts and Commitments. All agreements which materially affect Bio-Tracking to which Bio-Tracking is a party or by which Bio-Tracking or any of its property is bound which exist as of the date of execution of this Agreement have been filed as exhibits to documents filed by Bio-Tracking (collectively the "Contracts") with the Securities and Exchange Commission (the "SEC") under the Securities Exchange Act of 1934. Bio-Tracking is not in default with respect to any material term or condition of any such Contract, nor has any event occurred which through the passage of time or the giving of notice, or both, would constitute a default hereunder.
Section 4.12 Compliance with Laws. Bio-Tracking is not in violation of any applicable order, judgment, injunction, award or decree nor is it in violation of any Federal, state, local or foreign law, ordinance or regulation or any other requirement of any governmental or regulatory body, court or arbitrator, other than those violations which, in the aggregate, would not have a material adverse effect on Bio-Tracking and Bio-Tracking has not received written notice that any violation is being alleged.
Section 4.14 Stop Trade Orders. To Bio-Tracking's knowledge, there are no pending, and there have never been any, stop trade orders issued against Bio-Tracking or any of its directors or officers or those of any affiliates of Bio-Tracking by any securities regulatory authority in the United States.
Section 4.15 Regulatory Investigations. To Bio-Tracking's knowledge, there are no investigations or inquiries pending against Bio-Tracking or its directors or officers by any stock exchange, securities regulatory authority, taxing authority or any other governmental department or agency.
Section 4.16 Corporate Records. All of the minute books and corporate and financial records of Bio-Tracking are, or prior to the Closing will be, in all material respects, complete, up to date and accurate
Section 4.17. Material Information. This Agreement, the Schedules hereto and all other information provided in writing by Bio-Tracking or its representatives thereof to the shareholders, taken as a whole, do not contain any untrue statement of a material fact or omit to state a material fact necessary to make any statement contained herein or therein not misleading. There are no facts or conditions, which have not been disclosed to the Shareholders in writing which, individually or in the aggregate, could have a material adverse effect on Bio-Tracking or a material adverse effect on the ability of Bio-Tracking to perform any of its obligations pursuant to this Agreement.
ARTICLE V COVENANTS AND AGREEMENTS
The Shareholders and Bio-Tracking covenant and agree as follows:
Section 5.01. Conduct of Business in the Ordinary Course. From the date hereof through the Closing Date, the Shareholders shall cause NORD to conduct its business substantially in the manner in which it is currently conducted and, without the prior written consent of Bio-Tracking, not to undertake any of the actions specified in Section 3.11 nor enter into any Contract described in Section 3.17.
Section 5.02. Preservation of Permits and Services. From the date hereof through the Closing Date, the Shareholders shall cause NORD to use its best efforts and Bio-Tracking shall use its best efforts to preserve any permits in full force and effect and to keep available the services of their respective present officers, employees, consultants and agents and preserve their goodwill.
Section 5.03. Litigation. (a) From the date hereof through the Closing Date, the Shareholders shall notify Bio-Tracking promptly of any actions or proceedings of the type described in Section 3.15 that from the date hereof are threatened or commenced against NORD or against any officer, director, employee, properties or assets of NORD with respect to its affairs, or against any of the NORD Shares and of any requests for information or documentary materials by any governmental or regulatory body in connection with the transactions contemplated hereby.
(b) From the date hereof through the Closing Date, Bio-Tracking shall notify the Shareholders promptly of any actions, suits or claims or legal, regulatory, administrative or arbitration proceedings that from the date hereof are threatened or commenced against Bio-Tracking or against any officer, director, employee, properties or assets of Bio-Tracking with respect to its affairs and of any requests for information or documentary materials by any governmental or regulatory body in connection with the transactions contemplated hereby.
Section 5.04. Conduct of the Shareholders, NORD and Bio-Tracking Pending the Closing. From the date hereof through the Closing Date, (a) the Shareholders shall use, and the Shareholders shall cause NORD to use its best efforts to conduct its affairs in such a manner so that, except as otherwise contemplated or permitted by this Agreement, the representations and warranties contained in Article III shall continue to be true and correct on and as of the Closing Date as if made on and as of the Closing Date, (b) Bio-Tracking shall use its best efforts to conduct its affairs in such a manner so that, except as otherwise contemplated or permitted by this Agreement, the representations and warranties contained in Article IV shall continue to be true and correct on and as of the Closing Date as if made on and as of the Closing Date, (c) the Shareholders shall promptly notify Bio-Tracking of any event, condition or circumstance occurring from the date hereof through the Closing Date that would constitute a violation or breach of this Agreement by the Shareholders, and (d) Bio-Tracking shall promptly notify the Shareholders of any event, condition or circumstance occurring from the date hereof through the Closing Date that would constitute a violation or breach of this Agreement by Bio-Tracking.
Section 5.05. Corporate Examinations and Investigations. Prior to the Closing Date, Bio-Tracking shall be entitled, through its employees and representatives, to make such investigation of the assets, Liabilities, properties, business and operations of NORD , and such examination of the books, records, tax returns, results of operations and financial condition of NORD, as Bio-Tracking wishes. Any such investigation and examination shall be conducted at reasonable times and under reasonable circumstances and the Shareholders and NORD and the employees and representatives of NORD, including without limitation, their counsel and independent public accountants, shall cooperate fully with such representatives in connection with such review and examination.
Section 5.06. Acquisition Proposals. From the date hereof through the Closing Date, neither the Shareholders nor NORD, nor any of the officers, directors, affiliates, employees, representatives or agents of NORD, shall, directly or indirectly, solicit, initiate or participate in any way in discussions or negotiations with, or provide any information or assistance to, or enter into any Contract with any person, entity or group (other than Bio-Tracking) concerning any acquisition of a substantial equity interest in, or in a merger, consolidation, liquidation, dissolution, disposition of assets of NORD or any disposition of any of the NORD Shares (other than pursuant to the transactions contemplated by this Agreement) (each, an “Acquisition Proposal”), or assist or participate in, facilitate or encourage any effort or attempt by any other person or entity to do or seek to do any of the foregoing. The Shareholders shall promptly communicate to Bio-Tracking the terms of any Acquisition Proposal which any of them may receive.
Section 5.07. Further Assurances. Each of the parties shall execute such documents and other papers and take such further actions as may be reasonably required or desirable to carry out the provisions hereof and the transactions contemplated hereby. Each such party shall use its best efforts to fulfill or obtain the fulfillment of the conditions to the Closing as promptly as practicable.
Section 5.08. Charter Amendments. Prior to the Closing Date, Bio-Tracking shall cause the Articles of Incorporation and By-laws of Bio-Tracking to be amended (a) to set the number of directors at five (5), (b) cause a “reverse split” of its issued and outstanding shares, prior to the issuance of the Bio-Tracking Shares at a ratio of 10:1 while maintaining the number of authorized shares of common stock at 25 million; and, (c) to change the name of Bio-Tracking to “Major League Sports Corporation.”. Bio-Tracking shall file with the SEC any and all forms necessary to conduct the foregoing amendments in accordance with U.S. securities laws and regulations. On or prior to the Closing Date, Bio-Tracking shall cause one (1) designees of the Shareholders to be elected as directors of Bio-Tracking effective immediately following the Closing. There shall be no other amendments of, or modifications to, the Articles or Certificate of Incorporation or By-laws of Bio-Tracking and no amendments or modification to the Articles of Incorporation or By-laws of NORD.
Section 5.09. Disposition of Subsidiaries. Prior to the Closing Date, Bio-Tracking shall sell or otherwise transfer ownership of any of its existing subsidiaries if any and remove all consolidated debt related to such subsidiaries from its financial statements.
Section 5.10. Capital Raising Activities. (a) Bio-Tracking shall immediately commence the offer and sale of approximately 20,000,000 shares to fund marketing activities post closing of this acquisition with NORD.
(b) At the Closing, Bio-Tracking shall have no more than 340,000,000 shares of common stock issued and outstanding, whereas the company will issue 180,000,000 to the NORD shareholders post a reverse split of 1:12 and 6,000,000 shares to Finkelstein Capital or nominees as a finders.
Section 5.11. Delivery of Financial Statements. (a) On or before the Closing Date, the Shareholders shall cause NORD to provide the following financial statements to Bio-Tracking, which shall collectively be referred to as the “Financial Statements”.
(i) Audited balance sheets as of the end of each of the two most recent fiscal years or such shorter period as NORD (including its predecessors) has been in existence;
(ii) Audited statements of income and cash flow for each of the three fiscal years preceding the date of the audited balance sheet referred to in (1) above or such shorter period as NORD (including its predecessors) has been in existence;
(iii) An interim balance sheet as of December 31, 2004; and
(vi) For the interim period between the date of the audited balance sheet referred to in (1) above and December 31, 2004, and for the corresponding period of the preceding fiscal year, statements of income and cash flows.
(b) The audited financial statements referred to in (a)(i) and (a)(ii) above shall be audited by a independent certified public accountants or independent chartered accountants that have been duly registered and in good standing with the Securities and Exchange Commissions’ PCAOB. The interim financial statements referred to in (a)(iii) and (a)(vi) above may be unaudited.
(c) NORD shall also provide a letter from its auditors referred to in (b) above in which the auditors shall state that they will be able to complete its review of NORD’s interim financial statements for filing, as required by the Securities and Exchange Commission and provide assistance to Bio-Tracking’s auditors in the preparation of pro forma financial statements of Bio-Tracking showing the affects of the acquisition of NORD, within 75 days after the Closing.
Section 5.12 Public Announcements. Except as required by any applicable law, rule or regulation, prior to the Closing NORD shall not issue nor permit to be issued any press release or otherwise make or permit to be made any public statement with respect to the transactions contemplated by this Agreement without the prior written consent of Bio-Tracking.
ARTICLE VI CONDITIONS PRECEDENT TO THE OBLIGATION OF BIO-TRACKING TO CLOSE
The obligation of Bio-Tracking to enter into and complete the Closing is subject, at Bio-Tracking’s option acting in accordance with the provisions of this Agreement with respect to the termination hereof, to the fulfillment on or prior to the Closing date of the following conditions, any one or more of which may be waived by it, to the extent permitted by law.
Section 6.01. Representations and Covenants. The representations and warranties of the Shareholders contained in this Agreement shall be true and correct on and as of the Closing Date with the same force and effect as though made on and as of the Closing Date, except that any of such representations and warranties that are give as of a particular date and relate solely to a particular date or period shall be true as of such date or period. The Shareholders shall have performed and complied with all covenants and agreements required by this Agreement to be performed or complied with by them on or prior to the Closing Date. The Shareholders shall have delivered to Bio-Tracking a certificate dated the Closing Date, and signed by each Shareholder to the foregoing effect.
Section 6.02. Governmental Permits and Approvals. All approvals, authorizations, consents, permits and licenses from governmental and regulatory bodies required for the transactions contemplated by this Agreement and to permit the business currently carried on by NORD to continue to be carried on by NORD substantially in the same manner immediately following the Closing Date shall have been obtained and shall be in full force and effect and without conditions or limitations reasonably unacceptable to Bio-Tracking, and Bio-Tracking shall have been furnished with appropriate evidence, reasonably satisfactory to it and its counsel, of the granting of such approvals, authorizations, consents, permits and licenses. There shall not have been any action taken by any court, governmental or regulatory body then prohibiting or making illegal on the Closing Date the transactions contemplated by this Agreement.
Section 6.03. Third Party Consents. All consents, permits and approvals from parties to contracts with NORD that may be required in connections with the performance by the Shareholders of their obligations under this Agreement or the continuance of such contracts with NORD in full force and effect after the Closing shall have been obtained.
Section 6.04. Litigation. No action, suit or proceeding shall have been instituted and be continuing or be threatened by any Person to restrain, modify or prevent the carrying out of the transactions contemplated hereby, or to seek damages in connection with such transactions, or that has or could have a material adverse effect on NORD.
Section 6.05 No Change in Capitalization. On the Closing Date, the capitalization of NORD shall be as represented in Section 3.02.
Section 6.06. Reimbursement of Expenses. At the Closing, NORD will pay up to US$5,000 non-refundable fee to the Escrow Agent as reimbursement to Bio-Tracking for various fees and expenses of Bio-Tracking and/or its affiliates that they have or will disbursed for completion of this transaction.
Section 6.07. Board and Shareholder Approval. Prior to the Closing, NORD will obtain from its Board of Directors and its shareholders approval of this Agreement and the transactions contemplated hereby.
Section 6.08. Cancellation Fee. In the event that the transactions contemplated by this Agreement are not closed by June 15, 2005 as the result of any breach by NORD of its obligations hereunder, a material misrepresentation by NORD to Bio-Tracking, or the failure of NORD or its auditors’ inability or failure or refusal to provide the necessary audits and reviews of the Financial Statements as required pursuant to Section 5.12 above, NORD shall pay to Bio-Tracking a cancellation fee of US$5,000.
ARTICLE VII CONDITIONS PRECEDENT TO THE OBLIGATION OF THE SHAREHOLDERS TO CLOSE
The obligation of the Shareholders to enter into and complete the Closing is subject, at the Shareholder’s option acting in accordance with the provisions of this Agreement with respect to the termination hereof, to the fulfillment on or prior to the Closing Date of the following conditions, any one or more of which may be waived by it, to the extent permitted by law.
Section 7.01. Representations and Covenants. The representations and warranties of Bio-Tracking contained in this Agreement shall be true and correct on and as of the Closing Date with the same force and effect as though made on and as of the Closing Date, except that any of such representations and warranties that are give as of a particular date and relate solely to a particular date or period shall be true as of such date or period. Bio-Tracking shall have performed and complied with all covenants and agreements required by this Agreement to be performed or complied with by them on or prior to the Closing Date. Bio-Tracking shall have delivered to the Shareholders a certificate dated the Closing Date, and signed by an appropriate officer of Bio-Tracking to the foregoing effect.
Section 7.02. No Change in Capitalization. On the Closing Date, the capitalization of Bio-Tracking shall be as represented in Section 4.05, plus the issuances as contemplated in Section 5.10 hereof.
Section 7.03. Appointment of NORD’s Board Nominees; Resignation of Current Directors. At the Closing, Bio-Tracking shall deliver or cause to be delivered the resignations and releases and indemnification of all the officers of Bio-Tracking. Bio-Tracking shall also cause, at closing that all the directors of Bio-Tracking shall deliver seriatim their resignations together with releases and indemnifications in favor of two NORD nominees and that NORD shall as a result have 2 two out of 5 five directors post closing.
Section 7.04. Filing of Periodic Reports. From the date of this Agreement up to the Closing Date, Bio-Tracking will file with the U.S. Securities and Exchange Commission any and all periodic reports required to be filed by Bio-Tracking pursuant to Section 13(g) of the Securities Exchange Act of 1934 and at the Closing, Bio-Tracking shall be current in such filings for the past two (2) years. All such reports filed from the date of this Agreement shall be, as of the time of filing, accurate, not misleading and complete in all material respects and the financial statements included therewith shall have been prepared in accordance with generally accepted accounting principles.
Section 7.05. Quotation on OTC/BB. Prior to the Closing Date, Bio-Tracking shall on a best effort basis have completed its application ready to be filed, through a licensed market maker, for approval of its common stock to be quoted on the OTC/Bulletin Board.
Section 7.06. Financial Liabilities at Closing. As of the Closing Date, Bio-Tracking shall have no assets and no liabilities.
Section 7.07. Board and Shareholder Approval. (a) Prior to the Closing, Bio-Tracking shall obtain the approval of its Board of Directors of this Agreement and the transactions contemplated hereby.
(b) Bio-Tracking shall cause an Information Statement on Schedule 14C to be filed with the SEC and mailed to its shareholders of record disclosing that Bio-Tracking has entered into this Agreement and also the transactions contemplated hereby. Such Information Statement shall also provide that Bio-Tracking intends to change its name to “Nord Oil International Inc.”, along with any other action of which Bio-Tracking requires shareholder approval in order to close this Agreement in accordance with the terms hereof. Shareholders of Bio-Tracking holding at least a majority of Bio-Tracking’s issued and outstanding shares of common stock, as of the record date, shall approve of this Agreement and the transactions contemplated hereby either by proxy or written consent.
Section 7.08. Cancellation Fee. In the event that the transactions contemplated by this Agreement are not closed by June 15, 2005 as the result of a material misrepresentation by Bio-Tracking in any of its periodic reports filed with the SEC through to current filing or any breach by Bio-Tracking of its obligations hereunder or a material misrepresentation by Bio-Tracking to NORD, Bio-Tracking shall pay to NORD a cancellation fee of US$5,000.
Section 7.09 Indebtedness to and from Officers, Directors and Stockholders. Bio-Tracking is not indebted to any officer, director, or stockholder of Bio-Tracking in any amount whatsoever.
ARTICLE VIII POST-CLOSING COVENANTS
The parties hereto hereby make the following covenants and promises to the other with the express understanding that such covenants and promises shall survive past the Closing Date.
Section 8.01. Recapitalization. The Shareholders shall not vote in favour of any reverse split of Bio-Tracking’s stock that is proposed by the Board of Directors of Bio-Tracking or any shareholders of Bio-Tracking at any time during the two (2) year period that commences on the Closing Date except for the planned 1:12 reverse split.
Section 8.02. Transfer Agent. The Shareholders and NORD shall cause Bio-Tracking to continue to use Bio-Tracking’s current transfer agent, Interwest Transfer, for a period of two (2) years that commences on the Closing Date unless otherwise determined by the Bio-Tracking board post closing.
ARTICLE IX MISCELLANEOUS
Section 9.1 Timing. Time is of the essence of this Agreement and each party hereto agrees and covenants to use their reasonably best efforts to complete the transactions contemplated hereby in a timely manner.
Section 9.2 Additional Documentation. The parties will execute and deliver such further documents and instruments and do all such acts and things as may be reasonably necessary or requisite to carry out the full intent and meaning of this Agreement and to effect the transactions contemplated by this Agreement.
Section 9.3 Assignment. This Agreement may not be assigned by any party hereto without the prior written consent of all parties to this Agreement.
Section 9.4 Execution in Counterparts. This Agreement may be executed in several counterparts, each of which will be deemed to be an original and all of which will together constitute one and the same instrument.
Section 9.5 Expenses. Each party will pay its legal expenses incurred in connection with the transactions contemplated hereby, whether or not such transactions are consummated; provided, however, the parties shall share in the cost of the preparation of this Agreement and the preparation and mailing of an Information Statement to BIO-TRACKING’s shareholders seeking approval of this Agreement and the transactions, which is estimated to be approximately $20,000 USD.
Section 9.6 Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Nevada, without regard to principles of conflicts of law.
IN WITNESS WHEREOF the parties hereto have set their hand and seal as of the day and year first above written.
“SHAREHOLDERS” BIO-TRACKING CAPITAL II INC., a Florida corporation
EXHIBIT B ALLOCATION OF BIO-TRACKING SHARES TO NORD SHAREHOLDERS
Name of NORD Shareholder and or nominee(s) Number of NORD Shares Held Number of Bio-Tracking Shares to be Received Monimpex N/A 13,500,000 Finkelstein Capital and or nominee(s) N/A 13,500,000 80,000,000 25,000,000 10,000,000 10,000,000 10,000,000 10,000,000 8,000,000
posted
Use the lack of dissemination of info to your advantage, ill be picking up more while the prices stay artificially low
-------------------- Choosing individual stocks without any idea of what you're looking for (or without reliable information) is like running through a dynamite factory with a burning match. You may live, but your still an idiot. Posts: 5320 | From: Syracuse, NY | Registered: Apr 2005
| IP: Logged |
-------------------- "Whether you think that you can, or that you can't, you are usually right." - Henry Ford Posts: 798 | Registered: Jun 2004
| IP: Logged |
Composite Indicator -- Signal -- -- Strength -- -- Direction -- Trend Spotter (TM) Buy Minimum Weakest
Short Term Indicators 7 Day Average Directional Indicator Buy Average Weakest 10 - 8 Day Moving Average Hilo Channel Buy Minimum Weakest 20 Day Moving Average vs Price Buy Average Weakest 20 - 50 Day MACD Oscillator Buy Maximum Strongest 20 Day Bollinger Bands Hold Bearish
Short Term Indicators Average: 80% - Buy
Medium Term Indicators 40 Day Commodity Channel Index Buy Minimum Weakest 50 Day Moving Average vs Price Buy Average Weakest 20 - 100 Day MACD Oscillator Buy Maximum Strongest 50 Day Parabolic Time/Price Buy Average Weakest
Medium Term Indicators Average: 100% - Buy
Long Term Indicators 60 Day Commodity Channel Index Buy Weak Weakest 100 Day Moving Average vs Price Buy Average Weakest 50 - 100 Day MACD Oscillator Hold Bullish
Long Term Indicators Average: 67% - Buy
Overall Average: 88% - Buy
as of close yesterday long term indicators are up 33%
Posts: 6008 | From: phoenix az | Registered: Mar 2005
| IP: Logged |
posted
Morning guys. I've been following this stock a little bit and have some questions. It does seem like an impressive undertaking on the company's part, which is attractive. They have done a descent job on telling everyone what's going on (R/S, etc.). My real question is, what's make anyone think the purchase of $2.5 billion is worth it. I just don't see them raising enough money with only the addition of 180 million shares. From what I can gather, the oil isn't even close to the $2.5B deal. Someone, make me a believer. I'd love to ride from .02 to .30 (even if it takes a year).
-------------------- If you don't sweat the pennies, you're not making any money. Posts: 2218 | Registered: Feb 2005
| IP: Logged |
posted
Still think we will not see the PPS rise this deserves yet do to there not being a PR about the SEC 8 filing...unless you go looking for it nobody will see it...gotta be patient!
Posts: 1052 | From: Coventry, RI, USA | Registered: Dec 2004
| IP: Logged |
posted
Chadsley, this portion of their PR (below) is where they got the $ 2.5 billion in value. A large portion of the potential seems to depend on if, in fact, the probable reserves are really there with the proven reserves. And remember, it's not just the stock BTSI is offering in this deal, Nord will still own over 80% of all of the stock after the R/S. But even the proven reserves would make this stock vastly undervalued IMO. Under the terms of the definitive agreement, the company will proceed to issue 180 million shares for 100% of the acquisition of Nord Oil's properties with proven reserves of 15 million barrels of oil and probable reserves of 33 million barrels; a deal valued at approximately $2.5 billion USD. The company will issue said shares post a reverse split of its common shares on a 1:12 basis, resulting in the total outstanding shares of the company to be approximately 216 million shares and where the shareholders of Nord Oil will own approximately 83%. Once the reverse split is executed and the shares issued, the company will proceed to change its name to Nord Oil International Inc.Posts: 798 | Registered: Jun 2004
| IP: Logged |
posted
In the filing they said they are offering 20mil shares after merger to raise additional capital. Authorized shares never to be over 340mil shares.
-------------------- If your reading this then obviously you have time to do research before you buy or sell a stock Posts: 143 | Registered: Jun 2005
| IP: Logged |
From my unnamed source,BTSI addresses investors concerns
We have read your email and understand your concern. You mentioned you were a "trader" and in such capacity you are very well placed to evaluate why stocks go up and down. However, since you are inquiring regarding such price movement, we can provide you with some basic understanding of market as it pertains to reverse mergers.
Several Cause could be responsible:
1. Profit taking from investors that got in on the ground level at $0.004 2. Selling pressure from "heritage" shareholders that have had the stock for 2 or 3 years without liquitity and are now taking advantage of the current price movement to exit with no regard to the new merger candidate i.e. NordOil. 3. Pinksheet syndrom of investors vs market makers
We believe that 1 and 2 are causing the price decline. Currently the company is widely held and many investors have lost faith in this shell and are not willing to stay the course of a success in the making.
Having said that, if you have any comments and or questions, please do not hesitate to give us a call. Also, please note that we are not currently reviewing investment and the board of directors have requested to hold any such approach until further notice. We will therefore provide you with a complete package once we are ready consider investments and we expect that such time to be September or October and we will send you a package at that time.
Sincerely,
BIO-TRACKING
PER: Jean-Francois Amyot President
-------------------- I never knew a Nickle was worth so much.... Posts: 470 | From: New Jersey | Registered: Mar 2005
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Wink]](wink.gif)
![[Big Grin]](biggrin.gif)
